On May 7, 2026 Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, reported financial results for the quarter ended March 31, 2026, and provided recent corporate highlights.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This quarter reflects continued progress across our pipeline as we advance Phase 1 dose-escalation studies for HWK-007 and HWK-016, with a third IND planned for HWK-206 mid-year," said Dave Lennon, PhD, President and CEO of Whitehawk Therapeutics. "We remain focused on high quality execution as we build toward initial data anticipated in 1H 2027, with the goal of delivering meaningful benefits for patients."

Q1 2026 and Recent Operational Highlights:

Continued to enroll patients into ongoing Phase 1 dose-escalation trials for HWK-007 and HWK-016.
HWK‑007 is being evaluated in patients with non-squamous, EGFR wild-type non-small cell lung cancer; platinum-resistant ovarian cancer; and endometrial cancer (NCT07444814).
HWK‑016 is being evaluated in patients with advanced ovarian and endometrial cancers (NCT07470853).
Presented comprehensive data highlighting preclinical proof-of-concept for Whitehawk’s next-generation ADC portfolio underpinned by its proprietary Carbon Bridge Cysteine Re-pairing (CBCR) platform. Data presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026 demonstrate a consistent preclinical profile for HWK-007, HWK-016 and HWK-206 characterized by potent tumor regressions, high plasma stability and favorable tolerability in non‑human primates, coupled with low systemic levels of free payload.
Presented real-world analysis confirming MUC16 as a highly expressed clinically relevant target for gynecologic cancers. Whitehawk presented data at the Society of Gynecologic Oncology (SGO) 2026 Annual Meeting that established MUC16 as the highest-expressing ADC target in ovarian cancer, at least two-fold higher than other emerging targets, and showed MUC16 is highly and stably expressed in the most aggressive and most common subtypes of endometrial cancer.
First Quarter 2026 Financial Results:

Cash, cash equivalents and short-term investments as of March 31, 2026, were $123.0 million as compared to $145.7 million as of December 31, 2025. Cash is anticipated to fund operations into 2028 based on current plans.
Research and development expenses were $17.2 million for the three months ended March 31, 2026, including development milestone expenses of $5.3 million under our license agreement with WuXi Biologics, as compared to $8.8 million for the quarter ended March 31, 2025.
Net loss for the three months ended March 31, 2026, was $22.2 million as compared to a net income of $73.0 million for the three months ended March 31, 2025. The prior year quarter included an $87.4 million gain on the sale of Aadi Subsidiary.
Anticipated Milestones:

HWK-206 – plan to submit an Investigational New Drug application to the U.S. Food and Drug Administration in mid-2026 for HWK-206 in small-cell lung cancer and neuroendocrine tumors; Phase 1 recruitment planned to start in Q3 2026.
HWK-007 and HWK-016 – ongoing recruitment into Phase 1 trials, with initial results expected in 1H 2027.

(Press release, Whitehawk Therapeutics, MAY 7, 2026, View Source [SID1234665355])

On May 7, 2026 Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") reported the Company entered into a global collaboration and license agreement with GSK. Under the collaboration, GSK has licensed Halozyme’s ENHANZE drug delivery technology for the development and potential commercialization of subcutaneous administration of multiple oncology targets, including antibody drug conjugates (ADCs), as well as an option for additional future drug targets.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to work with GSK to advance development of several oncology therapeutics. This agreement also marks our first collaboration on subcutaneous delivery of ADCs, where we believe subcutaneous delivery with ENHANZE may meaningfully improve the benefit–risk profile," said Dr. Helen Torley, President and Chief Executive Officer of Halozyme. "This collaboration reflects the continued recognition of ENHANZE as the gold standard for rapid, large-volume subcutaneous delivery, and underscores the value it provides to a growing number of leading pharmaceutical and biotechnology companies. Extending use of ENHANZE with ADCs represents a meaningful expansion of our potential addressable market, positions us at the forefront of a rapidly growing therapeutic class and reinforces the durability of our high-margin royalty revenue business."

"Novel approaches are required to reduce treatment burden for patients with cancer and help access easier forms of treatment," said Eric Richards, SVP Head of Medicine Development Leaders Oncology, GSK. "We see significant potential for subcutaneous formulations of several promising cancer targets, including ADCs, with ENHANZE and look forward to progressing the first clinical program."

GSK will make an upfront payment to Halozyme and potential future milestone payments. Halozyme will also be entitled to royalties on net sales of products that incorporate ENHANZE.

(Press release, Halozyme, MAY 7, 2026, View Source [SID1234665354])

On May 7, 2026 Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, reported participation at the following investor conferences:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BofA Securities Health Care Conference 2026
Format: Virtual fireside chat and one-on-one investor meetings
Presentation Date/Time: Wednesday, May 13, 2026 at 10:40 am PT
Location: Las Vegas, NV

TD Cowen’s 7th Annual Oncology Innovation Summit: Insights for ASCO (Free ASCO Whitepaper) & EHA (Free EHA Whitepaper)
Format: Fireside chat with Tyler van Buren
Presentation Date/Time: Tuesday, May 26, 2026 at 2:00 pm ET
Location: Virtual

Jefferies Global Healthcare Conference
Format: Hybrid fireside chat and one-on-one investor meetings
Presentation Date/Time: Wednesday, June 3, 2026 at 3:45 pm ET
Location: New York, NY

A live webcast of the presentations can be accessed by visiting the "For Investors" page on the Tyra Biosciences website and will be available for replay following the event.

(Press release, Tyra Biosciences, MAY 7, 2026, View Source [SID1234665353])

On May 7, 2026 Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), ("Amplia" or the "Company"), and the Australia New Zealand Gynaecological Oncology Group (ANZGOG) reported that they have entered into an agreement to conduct a new clinical study investigating the Company’s lead drug narmafotinib in ovarian cancer. Narmafotinib is a best-in-class FAK inhibitor currently undergoing clinical development in pancreatic cancer where it is showing promising efficacy combined with good tolerability.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The study is an investigator-initiated clinical trial led by Dr Gwo Yaw Ho of Monash Health and Monash University, and sponsored and coordinated through ANZGOG, an international cooperative clinical trials network spanning major hospitals across Australia and New Zealand. The study is expected to enrol approximately 15–20 patients with high-grade serous ovarian cancer (HGSOC) who demonstrate poor response to up-front standard-of-care platinum-based chemotherapy prior to planned interval debulking surgery.

The trial, to be called the PRROSE trial, will evaluate the safety of narmafotinib in combination with standard-of-care chemotherapy (carboplatin and paclitaxel) in this patient population. Approximately one in five ovarian cancer patients do not respond adequately to initial chemotherapy, limiting their ability to undergo surgery and contributing to poor clinical outcomes. This study is designed to address this significant unmet medical need.

The study will therefore also explore whether the addition of narmafotinib can increase the proportion of patients eligible for successful surgical resection. Extensive tissue and blood biomarkers will be examined for insight into narmafotinib’s mechanism of action to further enrich data provided from the study.

Dr Chris Burns, CEO and Managing Director of Amplia, commented: "We are very pleased to be collaborating with ANZGOG and Dr Ho on this promising study. Based on the compelling biological rationale for the potential of FAK inhibitors in ovarian cancer, a clinical program in this indication is clearly warranted. Patients with ovarian cancer who do not respond to initial chemotherapy have very limited treatment options and this study will provide an opportunity to assess whether narmafotinib can improve outcomes for these patients. This trial also represents an important step in broadening the clinical utility of our FAK inhibitor program."

Dr Gwo Yaw Ho, Lead Investigator, said: "This study reflects the strength of ANZGOG’s collaborative clinical trials network and its ability to bring together leading clinical investigators to address areas of high unmet need in gynaecological cancers. This trial builds on ANZGOG’s established capability to design and deliver rigorous, potentially practice-changing clinical research across Australia and New Zealand. The study is underpinned by a commitment to translating promising scientific approaches, such as Amplia’s, into well- conducted clinical trials that can generate meaningful evidence to inform future treatment options for women with ovarian cancer."

(Press release, Amplia Therapeutics, MAY 7, 2026, View Source [SID1234665352])

On May 7, 2026 OmniAb, Inc. (NASDAQ: OABI) reported financial results for the three months ended March 31, 2026, provided operating and partner program updates, and increased 2026 financial guidance.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"OmniAb experienced strong momentum during the first quarter as multiple partnered programs advanced into later-stage clinical development, reinforcing the diversity and value of our portfolio. With a very strong start to the year, we are raising our 2026 revenue guidance," stated Matt Foehr, Chief Executive Officer of OmniAb. "Continued progression of partner programs highlights the value of our technology platform and positions our business well for the future. Our innovation efforts continue to differentiate our platform as demonstrated by the launch of OmniUltra and our xPloration partner access program."

First Quarter 2026 Financial Results

Revenue for the first quarter of 2026 was $14.4 million, compared with $4.2 million for the same period in 2025, with the increase primarily related to milestone revenue.

Research and development expense was $9.6 million for the first quarter of 2026, compared with $12.6 million for the same period in 2025, with the decrease due to lower personnel expense, share-based compensation expense, and external expenses associated with legacy small molecule ion channel programs. General and administrative expense was $6.6 million for the first quarter of 2026, compared with $7.9 million for the same period in 2025, with the decrease primarily due to lower personnel expense, share-based compensation expense, and legal fees.

Amortization of intangibles increased to $6.0 million for the first quarter of 2026, compared with $3.2 million for the same period in 2025, primarily due to a $2.9 million non-cash impairment related to the discontinuation of certain legacy small-molecule ion channel programs.

Total costs and operating expenses were $22.3 million for the first quarter of 2026, compared with $23.0 million for the same period in 2025. Cash costs and operating expenses were $12.3 million for the first quarter of 2026, compared with $14.7 million for the same period in 2025 (see note regarding "Use of Non-GAAP Financial Measure" below for further discussion of this non-GAAP measure).

Net loss for the first quarter of 2026 was $7.7 million, or $0.06 per share, compared with a net loss of $18.2 million, or $0.17 per share, for the same period in 2025.

2026 Financial Guidance

OmniAb revises 2026 financial guidance and now expects revenue to be in the range of $28 million to $33 million, versus $25 million to $30 million previously, and costs and operating expenses to be in the range of $83 million to $88 million, versus $80 million to $85 million previously. Cash costs and operating expenses remain unchanged and are expected to be in the range of $50 million to $55 million (see note regarding "Use of Non-GAAP Financial Measure" below for further discussion of this non-GAAP measure). The Company now expects to end the year with cash and cash equivalents in the range of $33 million to $38 million, versus $30 million to $35 million previously. The full-year 2026 effective tax rate is expected to be approximately 0%.

First Quarter 2026 and Recent Business Highlights

During the first quarter of 2026, OmniAb entered into a new license agreement with Florida State University. As of March 31, 2026, the Company had 107 active partners and 409 active programs, including 32 OmniAb-derived programs in clinical development or being commercialized.

Business and partner highlights from the first quarter of 2026 and recent weeks included the following:

IMVT-1402 & batoclimab

The potentially registrational trial with IMVT-1402 in difficult-to-treat rheumatoid arthritis is fully enrolled, with topline data expected in the second half of this year. Topline data from the proof-of-concept trial with IMVT-1402 in cutaneous lupus erythematosus is also expected in the second half of this year.
Potentially registrational studies with IMVT-1402 in Graves’ disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy and Sjögren’s disease remain on track with topline data in GD and MG expected in 2027.
Immunovant announced topline data from its two Phase 3 studies evaluating batoclimab as a treatment for active, moderate-to-severe thyroid eye disease and intends to review future plans for the development of batoclimab with its partner HanAll Biopharma Co. Immunovant remains focused on rapidly advancing the clinical development of IMVT-1402.
TEV- ‘408

Teva Pharmaceuticals announced a funding agreement with Royalty Pharma of up to $500 million to accelerate the clinical development of Teva’s anti-IL-15 antibody TEV-‘408 for vitiligo.
Topline results of the Phase 1b trial evaluating TEV-‘408 for vitiligo are expected in the first half of this year. Topline results of the Phase 2a trial evaluating TEV-‘408 for celiac disease are expected in the second half of this year.
Precemtabart tocentecan (M9140)

At the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Gastrointestinal Cancers Symposium, pooled data on precemtabart tocentecan, a novel anti‑CEACAM5 antibody‑drug conjugate with a topoisomerase 1 inhibitor payload, from the PROCEADE-CRC-01 study in patients with metastatic colorectal cancer were presented that showed an objective response rate of 26.8% and median progression-free survival of 6.9 months. The overall safety profile was consistent with earlier data with no new or unexpected treatment-emergent adverse events.
Merck KGaA indicated that based on Phase 1 data, it plans to advance precemtabart tocentecan directly to Phase 3 trials in metastatic colorectal cancer, with study initiation anticipated in the second or third quarter of 2026.
OmniAb expects that multiple partner programs will be highlighted at the ASCO (Free ASCO Whitepaper) Annual Meeting taking place May 29 – June 2, 2026.

Conference Call and Webcast

OmniAb management will host a conference call with accompanying slides today beginning at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss this announcement and answer questions. To participate via telephone, please dial (833) 461-5787 using the conference ID 563758100. Slides, as well as the live and replay webcast, are available at View Source

(Press release, OmniAb, MAY 7, 2026, View Source [SID1234665351])